Evidence map›Paper›PMID 36515794›Full record

ArticleClinical rheumatology2023

Enteric Toll-like receptor 7 stimulation causes acute exacerbation in lupus-susceptible mice.

Yudai Takase, Mirei Shirakashi, Yuri Nishida, Masao Katsushima, Hideo Onizawa, Ryosuke Hiwa, Hideaki Tsuji, Koji Kitagori, Shuji Akizuki, Akira Onishi and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Yudai TakaseDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Sakyo-Ku Kyoto, Shogoin, 606-8507, Japan.
Mirei ShirakashiDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Sakyo-Ku Kyoto, Shogoin, 606-8507, Japan. millet30@kuhp.kyoto-u.ac.jp.ORCID http://orcid.org/0000-0003-1135-0463
Yuri NishidaDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Sakyo-Ku Kyoto, Shogoin, 606-8507, Japan.
Masao KatsushimaDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Sakyo-Ku Kyoto, Shogoin, 606-8507, Japan.
Hideo OnizawaDepartment of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Ryosuke HiwaDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Sakyo-Ku Kyoto, Shogoin, 606-8507, Japan.
Hideaki TsujiDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Sakyo-Ku Kyoto, Shogoin, 606-8507, Japan.
Koji KitagoriDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Sakyo-Ku Kyoto, Shogoin, 606-8507, Japan.
Shuji AkizukiDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Sakyo-Ku Kyoto, Shogoin, 606-8507, Japan.
Akira OnishiDepartment of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Ran NakashimaDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Sakyo-Ku Kyoto, Shogoin, 606-8507, Japan.
Kosaku MurakamiDivision of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hajime YoshifujiDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Sakyo-Ku Kyoto, Shogoin, 606-8507, Japan.
Masao TanakaDepartment of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Tatsuaki TsuruyamaDepartment of Drug Discovery Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Akio MorinobuDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Sakyo-Ku Kyoto, Shogoin, 606-8507, Japan.
Motomu HashimotoDepartment of Clinical Immunology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Kyoto University · JPOsaka Metropolitan University · JP

Funding

Grants-in-Aid 16K09890Grants-in-Aid 20K08773
6 · The paper itself

Abstract

Autoimmune diseases are often accompanied by acute exacerbation. However, the mechanism underlying systemic lupus erythematosus (SLE) flares remains unclear. We investigated whether short-term enteric Toll-like receptor 7 (TLR7) stimulation can exacerbate SLE using B6SKG mice, which spontaneously develop SLE due to a mutation in the zeta‒chain‒associated protein kinase 70 (Zap70) gene. Imiquimod (IMQ) or phosphate-buffered saline (PBS) were orally administered on B6WT and B6SKG mice every other day for 2 weeks. SLE exacerbation was assessed via fluorescent immunohistochemical staining of glomeruli for IgG and C3, hematoxylin and eosin staining of kidneys, and enzyme-linked immunosorbent assay for antinuclear antibody (ANA). Flow cytometry was used to evaluate germinal center B cells (GCBs), plasma cells, follicular helper T cells (Tfhs), regulatory T cells (Tregs), effector T cells (Th1s and Th17s), plasmacytoid dendritic cells (pDCs), conventional dendritic cells (cDCs), and macrophages (Mφs) in spleens. Oral administration of IMQ every other day for 2 weeks resulted in exacerbation of splenomegaly, increased IgG and C3 deposition in glomeruli, and increased ANA production in the B6SKG IMQ (SKG-IMQ) group compared to the B6SKG PBS (SKG-PBS) group; the percentages of GCBs, plasma cells, Tfhs, Th1s, pDCs, and Mφs were also increased in the SKG-IMQ group. Splenomegaly, IgG, and C3 deposition in glomeruli, and the percentages of GCBs, plasma cells, Tfhs, and Th1s were enhanced in SKG-IMQ mice compared with B6SKG mice topically treated with IMQ (SKG-ear-IMQ). Oral TLR7 stimulation in a Zap70 genetic mutation background can cause acute exacerbations of SLE. Key Points • The mechanism of SLE flares is not well understood. • We have created a model that causes short-term SLE exacerbations in mice with a genetic background. • IMQ administered orally causes more SLE in mice than transdermally.

Indexed as

Lupus Erythematosus, SystemicToll-Like Receptor 7AnimalsDendritic CellsImiquimodImmunoglobulin GMiceSplenomegalyImiquimodImmunoglobulin GToll-Like Receptor 7Acute exacerbationB6SKGOral administrationSystemic lupus erythematosus (SLE)Toll-like receptor 7

Identifiers

PMID36515794
OpenAlexW4311497839

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.